



ICTR-PHE 2012

<http://cern.ch/ICTR-PHE12>

ICTR-PHE 2012

International Conference
on Translational Research
in Radiation Oncology

Physics for
Health in Europe

First Announcement



February 27 – March 2, 2012

Centre International de Conférences de Genève (CICG)
International Conference Centre
Geneva, Switzerland

Organised in Collaboration with

ESO | ESTRO | EANM | EFOMP | ENLIGHT
ESA | ESF | ESR | ESRF | EU | EuCARD | ILL | PARTNER

Important dates:

Abstract submission and early registration deadline
Late registration

October 3, 2011
January 15, 2012



ICTR-PHE 2012



First ICTR-PHE 2012 Conference: Uniting Biology, Medicine and Physics to fight cancer

Dear Colleague,

On behalf of the Organizing Committee it is our privilege to invite you to attend ICTR-PHE 2012 (International Conference on Translational Research in Radio-Oncology and Physics for Health in Europe), which will take place in Geneva on February 27 – March 2, 2012.

This conference represents a new reality in Oncology, as it brings together two major events in the interdisciplinary field at the intersection of Medicine, Biology and Physics: the ICTR conference and CERN's Physics for Health workshop.

The ICTR conferences started in 2000 with the objective to update the radiation oncology community on the most recent advances in translational research, reinforce the synergies among clinicians, biologists and medical physicists, and, last but not least, trigger personal and institutional contacts favouring a more efficient collaboration between laboratories worldwide.

The first edition of the Physics for Health workshop was organised by CERN in February 2010 with the objective of reviewing the progress in the domain of physics applications in life sciences, stimulating the exchange between different teams and indicating the subjects most suitable for further studies in diagnosis and therapy. The workshop, which was the first of its kind, brought together some 400 healthcare professionals, biologists and physicists to examine the increasingly important interface between physics and health.

One of the main reasons to merge ICTR and PHE is to develop new strategies to treat cancer, by uniting biology and physics with clinics. These novel synergies will be the "red thread" that ICTR-PHE 2012 will follow during this 5-day conference. In order to catalyse stimulating exchanges and interactions between experts and young researchers, top-ranked abstracts will be included in the Forum Workshop and Meet the Professor sessions. ICTR-PHE 2012 will also pay a tribute to those institutions and individuals who significantly contribute to the development of translational research in oncology. Last, but not least, we hope to foster a friendly atmosphere which will result in positive exchange throughout the conference.

This Conference will develop further expansion of our partnership with industry, with concerted efforts in Research & Development and a common approach to emerging educational modalities in translational research. All this will be formalised through the publication of the Conference abstracts in a Supplement of "Radiotherapy and Oncology" fully dedicated to ICTR-PHE 2012.

Setting up the stage of a new international conference is always a challenge, requiring an optimal coordination between all the components of the enterprise. But we are strongly convinced that the efforts we will put forth for a better integration along tracks where radiation physics, biology and medicine intertwine, will be key to success.

The Organizing Committee of ICTR-PHE 2012 is looking forward to welcoming you to Geneva so book February 27 – March 2, 2012 in your agenda now!



Jacques Bernier and Manjit Dosanjh,
Conference Chairs



Kian K. Ang , Ugo Amaldi, Michael Baumann, Soeren M. Bentzen, Jacques Bernier, Sergio Bertolucci, Jean Bourhis , Jean-François Chatal, Alberto Del Guerra, Manjit Dosanjh, Marco Durante, Wolfgang Enghardt, Zvi Fuks, Ulli Köster, W. Gillies McKenna, R. Mohan, Steve Myers, Ken Peach, and Brad Wouters

Advisory Board



ICTR-PHE 2012

ICTR-PHE 2012 Scientific Committee (as of February 2011)

Advisory Board

Kian K. Ang (Pre-Clinical Strategies)
Ugo Amaldi (New Technologies)
Michael Baumann (Pre-Clinical Strategies)
Soeren M. Bentzen (Radiotherapy)
Jacques Bernier
Sergio Bertolucci
Jean Bourhis (Clinical Perspectives)
Jean-François Chatal (Nuclear Medicine)
Alberto Del Guerra (Detectors and Imaging)
Manjit Dosanjh
Marco Durante (Biology)
Wolfgang Enghardt (Detectors and Imaging)
Zvi Fuks (Clinical Perspectives)
Ulli Köster (Nuclear Medicine)
W. Gillies McKenna (Biology)
Rahde Mohan (Radiotherapy)
Steve Myers
Ken Peach (New Technologies)
Brad Wouters

Sections:

Biology

M. Durante, Darmstadt
W. G. Mc Kenna, Oxford
J.M. Brown, Stanford
B. Jones, Oxford
B. Wouters, Toronto

New Technologies

U. Amaldi, Novara
K. Peach, Oxford
S. Rossi, Milano
T. Haberer, Heidelberg

Pre-Clinical Strategies

K.K. Ang, Houston
M. Baumann, Dresden
M. Verheij, Amsterdam

Radiotherapy

S.M. Bentzen, Madison
R. Mohan, Houston
D.R. Olsen, Oslo
S. Korreman, Copenhagen

Nuclear Medicine

J.F. Chatal, Nantes
U. Köster, Grenoble
D. Lewis, CERN

Clinical Perspectives

J. Bourhis, Villejuif
Z. Fuks, New-York
J. Bernier, Genolier and Geneva
D. Brizel, Durham

Detectors and Imaging

W. Enghardt, Dresden
A. Del Guerra, Pisa
S. Bertolucci, CERN
P. Lecoq, CERN
D. Townsend, Singapore

ICTR-PHE 2012 Executive Committee

Jacques Bernier, Genolier and Geneva
Sergio Bertolucci, CERN
Alberto Costa, Milano

Manjit Dosanjh, CERN
Raymond Miralbell, Geneva
Steve Myers, CERN



ICTR-PHE 2012

SUPPORTING INSTITUTIONS

In collaboration with
The European School
of Oncology



CERN
European Organization
for Nuclear Research



European Society for Therapeutic
Radiology and Oncology



European Society for Therapeutic Radiology and Oncology

Under the auspices of the
European Organisation for
Research and Treatment of Cancer



Fondazione FARO, Geneva



Fondazione TERA, Novara



University of Geneva,
and Geneva University Hospital





Conference Arrangements and Organization

Venue

All sessions will be held at the Centre International de Conférences de Genève - International Conference Center of Geneva (CICG), conveniently located near the International Airport and major highways, the railway station, Lake Geneva and the historic old town. A vast choice of hotels offers the delegates first-rate hospitality just a stone's throw from the conference centre.

Conference Environment and Climate

Distinguished by its unique geographical position in the heart of Europe, state-of-the-art technology, and high-quality services, Geneva is the ideal venue for international events and a top conference centre where the cross-fertilization of ideas encourages an open mind and objective view of the world. Located between the Alps and the Jura mountains, at the extreme south-west of Switzerland and the Lake Léman, Geneva is the central cross-roads of Western Europe. Geneva is situated at a 373-meter altitude, which together with the lake, tempers the prevailing continental climate. In March temperatures usually range between 8 and 15°. Snow falls in the nearby Alps are frequent at this period of the year.

Registration

Registration will open on June 1st. Information will be available on the website <http://cern.ch/ICTR-PHE12>

Registration Fee

Early registration	Swiss Francs	400	(deadline: October 3, 2011)
Late registration	Swiss Francs	700	(deadline: January 15, 2012)
On site registration	Swiss Francs	1'000	

The registration fee covers access to the Conference, a copy of the final programme and abstract book, coffee breaks and lunches during the Conference. Fees transferred later than February 1, 2012 may not be credited to the Conference account prior to the Congress registration. Therefore, it is mandatory to provide the registration desk personnel with a copy of the transfer order as proof of payment. Registration fees (less a CHF 80.00 administrative charge) will be refunded only if notification of cancellation will have reached the Conference Secretariat before January 15, 2012. No refunds will be issued after this date and no-shows are not eligible for a refund. All refunds will be made within 3-4 weeks after the Conference. If you register but cannot attend the Conference, you may elect to pass on your registration to another person with your Organization.

Language

The language of the Conference will be English. No simultaneous translation is foreseen.

Conference Abstracts

The Conference abstracts will be published as a supplement to Radiotherapy and Oncology (Green Journal).

Accreditation, travel grants

A list of accreditations (European Accreditation Council for Continuing Medical Education (EACCME) and American Medical Association (AMA) will be regularly updated on the Conference website.



Projection facilities

Powerpoint and PDF files will be used.

Posters

All posters will be on continuous display throughout the Conference.

Technical Exhibition

An exhibition will take place in the Conference Center Main Hall, close to the lecture and poster presentation halls.



Swiss International Air Lines is proud to be the Official Carrier for the ICTR-PHE 2012 and is offering special Congress Fares to all participants. These Congress Fares offer reductions of up to 25% depending on the fare type, route and space availability. Congress Fares are valid on the entire SWISS route network for flights to Switzerland, including flights operated by partner airlines under an LX flight number. These fares are now bookable for the travel period 14 days prior to and 14 days after the event.

To take advantage of this offer, book easily and conveniently through SWISS.COM via the following link: www.swiss.com/event

Please enter your email address and the following **event code: 4004-3632-4041-9268**. The special SWISS congress fare is marked with a "C". It may not necessarily be the lowest fare but it offers flexibility in the event of rebooking or cancellation. SWISS looks forward to pampering you on board with typical Swiss hospitality.

Conference Executive Office

Department of Radio-Oncology, Clinique de Genolier

4, route du Muids, CH-1272 Genolier

Switzerland

Phone + 41.22.366.9959

Fax + 41.22.366.9961

E-mail addresses info-ictr-phe-2012@cern.ch



Scientific Programme

In the Arena

General Research Areas

Functional Imaging
Developmental Radiation Physics
Molecular Pathology and Oncology
Structural Biology
Human Cancer Genetics
Pre-Clinical Data

Experimental Therapeutics
Early clinical testing
Radiobiology in therapy and space science
Radioisotopes in diagnostics and therapy
Prospects in medical imaging
Novel technologies in radiation therapy

Specific Topics (non exhaustive list)

Molecular imaging	Drug radioresistance	DNA-interactive agents
Positron emission tomography	Molecular targeting	Prodrugs
New markers in CT/PET	Receptors	Drug delivery
Targeted imaging including hypoxia markers	Structure-activity relationships	Drug resistance and modifiers
Brachytherapy	Tumor hypoxia	Radiation interactive agents
Radio-surgery	Hypoxic cytotoxins	Immunotherapy and ionizing radiation
Navigation systems	Micro-environmental determinants of response to radiation	Hormonal agents
Single-Cell Microbeams	Tumor vasculature	Tumor tissue banks
Microbeam probes of cellular radiation response	Vascular disrupting agents	Track structure applications
Magnetic field research	Tumor endothelial cell interactions	Oxidative stress
Intensity modulated radiation therapy (IMRT)	Angiogenesis and metastasis inhibitors	Bystander effects and radiotherapy
Tomotherapy	Radiation effects on angiogenesis	Microdosimetry
Particle radiotherapy, hadrontherapy	Apoptosis pathway targeting agents	Genomic instability
Image-guided radiotherapy, tissue motion sparing normal tissues and critical organs	Proteasome inhibitors	Tumor susceptibility genes
Novel approaches in Quality Assurance Telematics	Stress pathway inhibitors	Radiation carcinogenesis
Biologic and physical optimization in treatment planning	Chromatin modifying agents	Epigenetics
Bio-mathematical approaches for experimental data	Cellular therapies and cytokines	Genomics
Novel approaches in fractionation alteration	Monoclonal antibodies and target toxins/nuclides	Proteomics
Gene expression profiling	Radiosensitizers: in vitro and in vivo models	Histones and response to radiation
Predictive assays	Radioprotectors	Ubiquitin system in cancer therapy
Cell cycle and response to treatment	Genetic control of cancer cell and normal tissue Radiosensitivity	Novel organisms for studying radiation response
Mechanisms of radiation induced cell death	Intra- and inter-cellular signaling cascades induced by radiation	Stem cells (tumor response and normal tissue damage)
How to develop a successful cancer drug (chemo-radiation approaches)?	Signal transduction modulators	Hyperthermia
Pitfalls in developing cancer treatment agents	Cyclins and CDKs	Photodynamic Therapy
Applications of proteomics and genomics in drug discovery	Telomerase-targeting agents	Radiobiology
Mechanistic combinations	Gene therapy and antisense approaches	Radiation oncology
Practical issues in tissue research	Optimising targets for angiogenic inhibition	Particle therapy
Tumor vaccines	Stroma as a target	Radiation therapy
AKT/PTEN/Survival pathways	DNA, protein, and membrane chemistry	Treatment plans in radiotherapy
New targeting strategies: basic mechanisms and clinical outcome	DNA damage recognition	Radioisotopes
	DNA repair in tumor and normal tissues	Nuclear medicine
	DNA adducts	Medical imaging
	Normal tissue radiobiology	Challenges for simultaneous PET-MRI
	Antimetabolites	Time of Flight PET
	Bioreductive agents	Treatment of moving targets
	Topoisomerase I / II inhibitors	Scanned ion beam therapy
	Tubulin-interacting agents	Linac
		Cyclotron
		Technology in emerging markets
		Comprehensive engineering in radiotherapy



ICTR-PHE 2012

SCIENTIFIC PROGRAMME AT A GLANCE

Monday 27 February	Tuesday 28 February	Wednesday 29 February	Thursday 1 March	Friday 2 March
Opening Ceremony		Keynote Lecture (ESTRO: Physics)	Keynote Lecture (G.H. Fletcher)	Proffered papers
Radiobiology in therapy and space science	Prospects in detectors and medical imaging	Plenary lectures (1 speaker/topic)	Forum	Symposium
<ul style="list-style-type: none"> Missing data in radiation effects in deep space. Missing data for Treatment Planning Systems in ion therapy. Radiobiological research for improving particle therapy. Treatment of radiation-resistant tumours. Future needs. 	<ul style="list-style-type: none"> Position-sensitive detectors. Compton cameras. New methods of photon detection. Time-of-Flight for PET. Challenges of hybrid PET/MRI. Fast image reconstruction algorithms for <i>in-situ</i> treatment planning. 	<ul style="list-style-type: none"> Physics meet Biology. Physics meet Clinics. In-room Imaging. 	<ul style="list-style-type: none"> Predictive tools: new algorithms. Tumor micro-environment. Physics. 	<ul style="list-style-type: none"> Cancer stem cells. Tumor radiosensitivity modulation. Physics.
LUNCH		Plenary lectures (1 speaker/topic)	EORTC session.	Forum
		<ul style="list-style-type: none"> Radio-isotopes in therapy. Biological adaptive radiotherapy. Improving precision in imaging and treatment. 	<ul style="list-style-type: none"> Oral Poster Presentation. Oral Poster Presentation. 	<ul style="list-style-type: none"> Repair mechanisms in tumor and normal cells. Drug-radiation interactions. Radiosensitization and radioprotection.
LUNCH		LUNCH	LUNCH	LUNCH
Radioisotopes in diagnostics and therapy	Novel Technologies and therapy	Symposium (3 speakers/session)	Keynote Lecture: (G. Adams: Biology).	Workshops
<ul style="list-style-type: none"> ⁹⁹Mg/⁹⁹Tc supply and ⁹⁹Mo production. Therapy of metastases and systemic tumours with radioisotopes. Clinical experience with commercial beta-radioisotopes coupled to antibodies. Role of radiotracers in drug development. 	<ul style="list-style-type: none"> New accelerators for medical applications. Gantries for ions. Scanning beams and moving targets. Future developments. 	<ul style="list-style-type: none"> Tumor targeting and normal tissue protection. Image-guided prescription and planning of RT. Long-term perspectives in Hadrontherapy. 	<ul style="list-style-type: none"> Tumor vascularization. Targeted therapies: from bench to bedside. Physics. 	<ul style="list-style-type: none"> Biology. Physics. Clinics.
		Symposium (3 speakers/session)	Workshops	Proffered papers
		<ul style="list-style-type: none"> New algorithms in treatment planning and delivery. MonteCarlo in treatment planning. Status and perspectives in radiology. 	<ul style="list-style-type: none"> Targeting signaling pathways. Normal tissues: from prediction to facts. Physics. 	<ul style="list-style-type: none"> Biology. Physics. Clinics.
				ESO Plenary Session
				<ul style="list-style-type: none"> 2 Lectures. E. van der Schueren Award
				<ul style="list-style-type: none"> 1 Lecture.